Insulet (NASDAQ:PODD) Price Target Raised to $355.00

by · The Cerbat Gem

Insulet (NASDAQ:PODD – Free Report) had its target price increased by UBS Group from $320.00 to $355.00 in a research report sent to investors on Friday morning,Benzinga reports. They currently have a neutral rating on the medical instruments supplier’s stock.

Other research analysts have also recently issued reports about the stock. Weiss Ratings restated a “hold (c)” rating on shares of Insulet in a report on Wednesday, October 8th. JPMorgan Chase & Co. increased their price objective on Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Royal Bank Of Canada boosted their price objective on shares of Insulet from $350.00 to $365.00 and gave the company an “outperform” rating in a report on Friday, October 10th. Canaccord Genuity Group lifted their price objective on shares of Insulet from $353.00 to $399.00 and gave the company a “buy” rating in a research note on Monday, September 29th. Finally, The Goldman Sachs Group lowered their price objective on Insulet from $399.00 to $375.00 and set a “buy” rating on the stock in a research report on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and a consensus price target of $371.38.

Get Our Latest Research Report on PODD

Insulet Stock Performance

Shares of PODD stock traded down $5.00 on Friday, reaching $314.83. The stock had a trading volume of 86,754 shares, compared to its average volume of 718,174. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The stock has a market cap of $22.16 billion, a P/E ratio of 95.49, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. Insulet has a 1 year low of $230.05 and a 1 year high of $353.50. The company has a 50 day simple moving average of $325.06 and a 200 day simple moving average of $310.30.

Insulet (NASDAQ:PODD – Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The firm had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company’s revenue for the quarter was up 29.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts expect that Insulet will post 3.92 EPS for the current year.

Insider Transactions at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The SEC filing for this sale provides additional information. 0.39% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Larson Financial Group LLC increased its stake in Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 81 shares during the last quarter. Zions Bancorporation National Association UT acquired a new position in Insulet in the first quarter valued at $26,000. SouthState Corp grew its holdings in shares of Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 76 shares during the last quarter. True Wealth Design LLC increased its position in shares of Insulet by 288.0% during the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 72 shares in the last quarter. Finally, Kozak & Associates Inc. purchased a new stake in shares of Insulet in the 2nd quarter valued at about $32,000.

Insulet Company Profile

(Get Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

See Also